Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Maureen Kenny
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.